Additional research on the mechanism verification and large‐scale cohort validation holds the potential benefit of probiotic manipulation or targeted metabolism interventions in NSCLC neoadjuvant anti‐PD‐1 immunochemotherapy. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.